Quantum solution is to lead the field by propelling drug discovery forward and foster increased innovation and, ultimately, better health worldwide.
FREMONT, CA: SGX-listed Singapore eDevelopment Limited's wholly-owned subsidiary Impact Biomedical announces the initiation of Quantum, its research program tailored to solve the impending pharmaceutical patent cliff threat.
The patent cliff, which arises when patents for drugs expire without being replaced with new drugs, is a serious threat to pharmaceutical firms. This depletes financial resources needed for the development of new drugs, which in turn lowers overall pharmaceutical innovation, including research. Typical drug development uses schemes that are less tenable without the patentability of the foregoing, the resources needed to develop a new drug based on cannabis cannot be secured.
Impact Biomedical's transition to the Quantum research program comes on the heels of the completion of the research and development stage of its existing biodefense intellectual portfolio, which is now moving to the licensing and commercialization phase. The portfolio, valued by independent experts at approximately US$1.39 billion as announced by the Group on 1 June 2020 includes Linebacker, a universal therapeutic designed to shadow the Panacea Project, a US Defense Advanced Research Projects Agency (DARPA) program to provide novel, multi-target therapeutics for unmet physiological needs; 3F BioFragrance, designed for the Open Air Defense Initiative, a strategy to protect locations where large numbers of people gather or transit; and Equivir, an OTC medication designed as an antiviral treatment and prophylactic comprising polyphenols that are GRAS or Generally Recognized as Safe, meaning its safety and behavior in humans is already well understood and therefore is designed to proceed directly to human trials.
Impact's Quantum is a new frontier in pharmaceutical development and a new class of medicinal chemistry that uses advanced methods to boost the efficacy and persistence of natural compounds and existing drugs while maintaining the safety profile of the original molecules. Instead of modifying functional groups, as is typically done presently in drug discovery, this new technique alters the behavior of molecules at the sub-molecular level. GRDG estimates that 65% of the World Health Organization Essential Medicines List can be improved and re-patented using Quantum. This approach can be leveraged to enhance natural patent compounds, which includes many substances used in traditional medicines.